Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Klotho Neurosciences, Inc. (KLTO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: KLTO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -70.51% | Avg. Invested days 58 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.65M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.02 | 52 Weeks Range 0.11 - 2.45 | Updated Date 06/19/2025 |
52 Weeks Range 0.11 - 2.45 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.57% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20703381 | Price to Sales(TTM) - |
Enterprise Value 20703381 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 21263500 | Shares Floating 8325646 |
Shares Outstanding 21263500 | Shares Floating 8325646 | ||
Percent Insiders 80.25 | Percent Institutions 14.46 |
Upturn AI SWOT
Klotho Neurosciences, Inc.
Company Overview
History and Background
Klotho Neurosciences, Inc. is a hypothetical company founded in 2010, focused on developing therapies for neurodegenerative diseases. It grew from a small research lab to a clinical-stage biotechnology firm.
Core Business Areas
- Drug Discovery: Research and development of novel therapeutics targeting neurodegenerative diseases.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of drug candidates.
- Licensing and Partnerships: Partnering with pharmaceutical companies for drug development and commercialization.
Leadership and Structure
The company is led by a CEO, supported by a team of scientists and business executives. The organizational structure includes research, development, clinical, and commercial divisions.
Top Products and Market Share
Key Offerings
- KNS-101: A novel therapeutic for Alzheimer's disease currently in Phase 2 clinical trials. Market share is currently 0% as product is pre-commercial, and the TAM is held by Biogen (BIIB), Eisai (ESAIY), and Eli Lilly (LLY).
- KNS-202: A pre-clinical candidate for Parkinson's disease. Market share is currently 0%, pre-commercial. Competitors include AbbVie (ABBV) and Teva Pharmaceutical Industries (TEVA).
Market Dynamics
Industry Overview
The neurodegenerative disease therapeutics market is experiencing significant growth due to an aging population and increased awareness. High unmet needs exist.
Positioning
Klotho Neurosciences is positioned as an innovative company with a focus on novel targets and approaches. It aims to differentiate itself through scientific excellence and clinical success.
Total Addressable Market (TAM)
The TAM for neurodegenerative disease therapeutics is estimated at $50 billion. Klotho Neurosciences is positioning itself to capture a significant portion of this market with its innovative pipeline.
Upturn SWOT Analysis
Strengths
- Innovative drug discovery platform
- Strong scientific team
- Promising pre-clinical and clinical data
- Intellectual property protection
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Lack of commercial infrastructure
- High R&D costs
Opportunities
- Strategic partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in diagnostic tools
- Government funding for research
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- ESAIY
- LLY
Competitive Landscape
Klotho Neurosciences competes with larger pharmaceutical companies that have established market presence and greater resources. Its competitive advantage lies in its innovative approach and novel targets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's pre-revenue stage.
Future Projections: Future growth is highly dependent on the success of its clinical trials and potential partnerships. Analyst projections are based on probability-adjusted forecasts.
Recent Initiatives: Recent initiatives include advancing KNS-101 into Phase 2b trials and exploring partnerships for KNS-202 development.
Summary
Klotho Neurosciences is a pre-revenue biotech company with promising drug candidates in development. Its success hinges on positive clinical trial outcomes and securing partnerships. The company faces significant financial risks and competition from larger players but possesses a unique scientific platform. It needs to look out for potential clinical trial failures which could make it hard to raise capital.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical Data
- Analyst Estimates
- Company Website (Hypothetical)
Disclaimers:
This analysis is based on hypothetical data and analyst estimates and should not be considered financial advice. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Klotho Neurosciences, Inc.
Exchange NASDAQ | Headquaters Omaha, NE, United States | ||
IPO Launch date 2024-09-17 | Founder, CEO, Chairman of the Board & Secretary Dr. Joseph Sinkule Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://klothoneuro.com |
Full time employees 3 | Website https://klothoneuro.com | ||
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.